Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:35 am
Author: Getaka|Social: XLinkedIn

Rossari Biotech Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹359.97Overvalued by 10.90%vs CMP ₹404.00

P/E (16.3) × ROE (12.2%) × BV (₹226.00) × DY (0.12%)

₹370.77Fairly Valued by 8.23%vs CMP ₹404.00
MoS: -9% (Negative)Confidence: 48/100 (Moderate)Models: 3 Under, 1 Fair, 5 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹385.1322%Fair (-4.7%)
Graham NumberEarnings₹355.6216%Over (-12%)
Earnings PowerEarnings₹128.5213%Over (-68.2%)
DCFCash Flow₹302.5713%Over (-25.1%)
Net Asset ValueAssets₹225.737%Over (-44.1%)
EV/EBITDAEnterprise₹655.179%Under (+62.2%)
Earnings YieldEarnings₹248.707%Over (-38.4%)
ROCE CapitalReturns₹641.799%Under (+58.9%)
Revenue MultipleRevenue₹562.975%Under (+39.3%)
Consensus (9 models)₹370.77100%Fairly Valued
Key Drivers: Wide model spread (₹129–₹655) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 7.0%

*Investments are subject to market risks

Investment Snapshot

65
Rossari Biotech Ltd scores 65/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health81/100 · Strong
ROCE 15.8% GoodROE 12.2% GoodD/E 0.00 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money45/100 · Moderate
FII holding down -1.66% (6mo) SellingDII holding up 0.66% MF buyingPromoter holding at 68.2% Stable
Earnings Quality50/100 · Moderate
OPM stable around 14% Steady
Quarterly Momentum68/100 · Strong
Revenue (4Q): +16% YoY GrowingProfit (4Q): +1% YoY Positive
Industry Rank70/100 · Strong
P/E 16.3 vs industry 64.9 Cheaper than peersROCE 15.8% vs industry 13.0% Above peersROE 12.2% vs industry 25.4% Below peers3Y sales CAGR: 12% Moderate

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:35 am

Market Cap 2,239 Cr.
Current Price 404
Intrinsic Value₹370.77
High / Low 768/373
Stock P/E16.3
Book Value 226
Dividend Yield0.12 %
ROCE15.8 %
ROE12.2 %
Face Value 2.00
PEG Ratio2.33

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Rossari Biotech Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Rossari Biotech Ltd 2,239 Cr. 404 768/37316.3 2260.12 %15.8 %12.2 % 2.00
Thirumalai Chemicals Ltd 2,171 Cr. 180 329/158 1270.00 %0.26 %4.13 % 1.00
Fineotex Chemical Ltd 2,428 Cr. 20.8 35.8/19.025.0 6.720.38 %23.8 %18.4 % 1.00
Camlin Fine Sciences Ltd 1,951 Cr. 102 335/96.2822 46.30.00 %11.0 %15.0 % 1.00
Grauer & Weil (India) Ltd 2,616 Cr. 57.7 111/49.718.6 22.00.87 %23.3 %17.6 % 1.00
Industry Average12,530.04 Cr712.4964.87182.870.55%12.98%25.40%6.41

All Competitor Stocks of Rossari Biotech Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 389406411483464473490498513580544586582
Expenses 335352353420400409425432448510476514513
Operating Profit 54555864646465666569687269
OPM % 14%13%14%13%14%13%13%13%13%12%12%12%12%
Other Income 1321411112221
Interest 5465434456668
Depreciation 16161415151615151818181820
Profit before tax 35373945484647484248465043
Tax % 26%22%26%26%28%25%26%27%25%28%27%26%23%
Net Profit 26292933343435353234343733
EPS in Rs 4.665.255.305.976.236.186.326.395.736.226.076.665.92

Last Updated: February 4, 2026, 9:46 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 25, 2026, 3:16 pm

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 5166007091,4831,6561,8312,0802,291
Expenses 4384955861,2991,4331,5811,8152,013
Operating Profit 78105124184223250265278
OPM % 15%17%17%12%13%14%13%12%
Other Income 149136857
Interest 3431322191825
Depreciation 1217234863606774
Profit before tax 6388107136144178185186
Tax % 28%26%25%28%26%26%26%
Net Profit 46658098107131136138
EPS in Rs 103.8212.8615.4517.7419.4523.6624.6324.87
Dividend Payout % 0%4%3%3%3%2%2%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)41.30%23.08%22.50%9.18%22.43%3.82%
Change in YoY Net Profit Growth (%)0.00%-18.23%-0.58%-13.32%13.25%-18.61%

Rossari Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2019-2020 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:%
5 Years:28%
3 Years:12%
TTM:12%
Compounded Profit Growth
10 Years:%
5 Years:16%
3 Years:12%
TTM:-1%
Stock Price CAGR
10 Years:%
5 Years:-5%
3 Years:-14%
1 Year:-29%
Return on Equity
10 Years:%
5 Years:14%
3 Years:13%
Last Year:12%

Last Updated: September 5, 2025, 1:10 pm

Balance Sheet

Last Updated: December 4, 2025, 1:53 am

MonthMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 410101111111111
Reserves 1192773987949041,0371,1741,240
Borrowings 8670874119218353
Other Liabilities 118118152442375401482484
Total Liabilities 2504715611,2551,3641,5671,8862,088
Fixed Assets 7494181607585578598630
CWIP 322011647140247
Investments 01803651638420
Other Assets 1733383796117128801,0631,190
Total Assets 2504715611,2551,3641,5671,8862,088

Reserves and Borrowings Chart

Cash Flow

MonthMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 7157482915243137
Cash from Investing Activity + -37-190-37-299-181-103-183
Cash from Financing Activity + -29157-25292611665
Net Cash Flow 523-142232-4419
Free Cash Flow 27-19-8-7120-83-21
CFO/OP 118%74%64%43%89%39%74%

Free Cash Flow

MonthMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow70.0038.00124.00176.00149.00131.0047.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 61577475788583
Inventory Days 59577563598090
Days Payable 1149510461566273
Cash Conversion Cycle 619467680103101
Working Capital Days 23226062497069
ROCE %38%29%24%18%18%16%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 68.44%68.44%68.35%68.34%68.32%68.32%68.27%68.19%68.18%68.18%68.18%68.15%
FIIs 7.46%6.12%5.74%4.14%4.02%3.83%3.74%3.74%3.98%3.48%2.70%2.32%
DIIs 15.09%17.71%17.68%18.06%17.74%16.87%17.34%17.47%17.59%17.84%18.18%18.25%
Public 9.01%7.73%8.23%9.45%9.90%10.98%10.64%10.60%10.24%10.50%10.95%11.25%
No. of Shareholders 96,63495,37195,2001,00,42398,8591,00,47597,18895,73592,85291,79191,38789,249

Shareholding Pattern Chart

No. of Shareholders

Rossari Biotech Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
SBI Small Cap Fund 2,016,342 0.33 113.82,016,7982025-12-08 04:48:22-0.02%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 2.002.002.002.002.00
Basic EPS (Rs.) 24.6623.6719.4617.8115.56
Diluted EPS (Rs.) 24.6323.6219.3817.7015.47
Cash EPS (Rs.) 36.5734.5630.6826.1919.73
Book Value[Excl.RevalReserv]/Share (Rs.) 214.12189.65165.93146.2578.72
Book Value[Incl.RevalReserv]/Share (Rs.) 214.12189.65165.93146.2578.72
Revenue From Operations / Share (Rs.) 375.74331.35300.22269.36136.60
PBDIT / Share (Rs.) 48.6046.5641.4335.5025.47
PBIT / Share (Rs.) 36.4935.6330.0226.7721.07
PBT / Share (Rs.) 33.2732.1225.9724.4720.49
Net Profit / Share (Rs.) 24.4623.6219.2717.4615.34
NP After MI And SOA / Share (Rs.) 24.6323.6619.4517.7415.45
PBDIT Margin (%) 12.9314.0513.7913.1718.64
PBIT Margin (%) 9.7110.759.999.9315.42
PBT Margin (%) 8.859.698.659.0815.00
Net Profit Margin (%) 6.507.126.416.4811.22
NP After MI And SOA Margin (%) 6.557.136.476.5811.30
Return on Networth / Equity (%) 11.5012.4711.7112.1319.62
Return on Capital Employeed (%) 14.8517.1516.2215.3126.61
Return On Assets (%) 7.198.317.847.7714.29
Long Term Debt / Equity (X) 0.080.030.030.000.00
Total Debt / Equity (X) 0.150.100.080.010.00
Asset Turnover Ratio (%) 1.201.251.261.631.37
Current Ratio (X) 1.941.992.082.072.36
Quick Ratio (X) 1.281.321.541.421.73
Inventory Turnover Ratio (X) 6.535.225.706.805.66
Dividend Payout Ratio (NP) (%) 2.022.112.562.813.16
Dividend Payout Ratio (CP) (%) 1.351.441.611.882.46
Earning Retention Ratio (%) 97.9897.8997.4497.1996.84
Cash Earning Retention Ratio (%) 98.6598.5698.3998.1297.54
Interest Coverage Ratio (X) 15.1113.2810.2415.4444.20
Interest Coverage Ratio (Post Tax) (X) 8.607.745.768.6027.62
Enterprise Value (Cr.) 3475.133801.343233.014985.625300.00
EV / Net Operating Revenue (X) 1.672.081.953.367.47
EV / EBITDA (X) 12.9114.7814.1525.5140.08
MarketCap / Net Operating Revenue (X) 1.612.041.983.397.60
Retention Ratios (%) 97.9797.8897.4397.1896.83
Price / BV (X) 2.823.563.596.2513.18
Price / Net Operating Revenue (X) 1.612.041.983.397.60
EarningsYield 0.040.030.030.010.01

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Rossari Biotech Ltd. is a Public Limited Listed company incorporated on 10/08/2009 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24100MH2009PLC194818 and registration number is 194818. Currently Company is involved in the business activities of Manufacture of organic and inorganic chemical compounds. Company's Total Operating Revenue is Rs. 1431.63 Cr. and Equity Capital is Rs. 11.07 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Chemicals - Speciality - OthersRossari House, Golden Oak, LBS Marg, Surya Nagar, Mumbai Maharashtra 400079Contact not found
Management
NamePosition Held
Mr. Edward MenezesExecutive Chairman
Mr. Sunil ChariManaging Director
Mr. Aseem DhruIndependent Director
Ms. Aparna SharmaIndependent Director
Ms. Esha AchanIndependent Director
Mr. Gurudas ArasIndependent Director

FAQ

What is the intrinsic value of Rossari Biotech Ltd and is it undervalued?

As of 15 April 2026, Rossari Biotech Ltd's intrinsic value is ₹370.77, which is 8.23% lower than the current market price of ₹404.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (12.2 %), book value (₹226), dividend yield (0.12 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Rossari Biotech Ltd?

Rossari Biotech Ltd is trading at ₹404.00 as of 15 April 2026, with a FY2026-2027 high of ₹768 and low of ₹373. The stock is currently near its 52-week low. Market cap stands at ₹2,239 Cr..

How does Rossari Biotech Ltd's P/E ratio compare to its industry?

Rossari Biotech Ltd has a P/E ratio of 16.3, which is below the industry average of 64.87. Trading at a steep discount to peers could signal a value opportunity or reflect concerns about the company's fundamentals.

Is Rossari Biotech Ltd financially healthy?

Key indicators for Rossari Biotech Ltd: ROCE of 15.8 % indicates efficient capital utilization. Dividend yield is 0.12 %.

Is Rossari Biotech Ltd profitable and how is the profit trend?

Rossari Biotech Ltd reported a net profit of ₹136 Cr in Mar 2025 on revenue of ₹2,080 Cr. Compared to ₹98 Cr in Mar 2022, the net profit shows an improving trend.

Does Rossari Biotech Ltd pay dividends?

Rossari Biotech Ltd has a dividend yield of 0.12 % at the current price of ₹404.00. The company pays dividends, though the yield is modest.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Rossari Biotech Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports